Position Summary
The role of the Senior Manager is to manage statistical programming activities to ensure they are appropriately planned and executed for all assigned Phase I?IV clinical studies sponsored by Allergan and its partners. This senior level position serves as a compound lead, independently performs
statistical programming for clinical studies and integrated summaries, and prepares responses to requests from regulatory authorities.
The employee must conduct their work activities in compliance with all relevant laws, regulations, and
regulatory guidelines as well as all Allergan policies and procedures.
Key Duties / Responsibilities
Role: Statistical Programmer Oversight: Low to Moderate
Provide programming and documentation support for multiple studies with good quality
Review statistical analysis plans for all assigned studies and integrated summaries and provide comments to study biostatistician
Create ADaM data set specifications for all assigned studies and integrated summaries
Ensure study analysis is consistent with standard templates and specifications
Lead the Statistical Programming submission support, including managing timelines, tasks, and resources
Follow timelines for assigned study tasks
Contribute to development of new standard templates
Review and author standard operating procedures and supporting documents related to Statistical Programming processes
Coordinate own task assignments
Support urgent regulatory agency requests
Participate in a Statistical Programming process improvement initiative(s)
Participate in a Statistical Science and Programming process improvement initiative(s)
Contribute to cross?functional process improvement initiative(s)
In addition, the incumbent is one of the key contacts for Statistical Science and Data Management and Clinical Programming. External interfaces include: contract research organizations (CRO), functional service providers (FSP), and other vendors or consultants.
Minimum Requirements
MS in statistics or equivalent with at least 6+ years experience in Statistical Programming supporting drug development, submission, and approval in the pharmaceutical/biotech/device industry or CRO Or Bachelor's degree with at least 8+ years experience in Statistical Programming supporting drug development, submission, and approval in the pharmaceutical/biotech/device industry or CRO
Minimum four (4) years project management experience in statistical programming or related field
Knowledge:
Excellent knowledge of SAS computer package and Unix/Linux computing environment
Knowledge of CDISC foundational standards
A thorough knowledge of good programming practices and methodology
Good knowledge of clinical trial methodologies, drug development, and FDA GCP/ICH regulatory guidelines regarding statistical programming
Proficient with Microsoft Word, Microsoft Excel, Microsoft PowerPoint, Microsoft Outlook, and Adobe Acrobat
Skills/Competencies:
Ability to support and prioritize multiple projects and the work of other statistical programmers
Ability to multitask
Ability to influence others without direct reporting relationships
Ability to take initiative
Demonstrated strengths in the following areas:
Oral and written communication skills
Planning and organizational skills
Decision making, judgement and problem solving skills
Project management skills
Leadership Skills
Chicago, IL
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström’s macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia.
Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; and Calico Life Sciences LLC. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.